Send Enquiry      
Global Locations

N-Methyl-2-(1-methylethyl)-4-thiazolemethanamine dihydrochloride

CS-O-10629 Available for Dispatch by 5-Jul-2022

N-Methyl-2-(1-methylethyl)-4-thiazolemethanamine dihydrochloride

CS-O-10629
Intermediates

Available for Dispatch by 5-Jul-2022
50 mg x
$ 40.00
100 mg x
$ 50.00
500 mg x
$ 105.00
Looking for Custom QTY ? Click to request a quote



Item removed. Undo

PRODUCT INFO

Compound : N-Methyl-2-(1-methylethyl)-4-thiazolemethanamine dihydrochloride
CAT No. : CS-O-10629
Parent API : Cobicistat
CAS No. : 1185167-55-8
Category : Intermediates
Mol. Weight: 243.20
Mol. Formula : C8H16Cl2N2S
Controlled Substance : NO
Purity : >98%
Therapeutic : Synthetic Peptides
USAGE
Application : NULL
References : NULL
SHIPPING INFO
Custom Duty : Applicable
Documents:  View Sample COA   View Sample MSDS
Port of Loading : Canada
Expected Dispatch : 2-3 Weeks
PAYMENT INFO
Taxes : Not Applicable
Refund Policy : 30-days money back

More information about Cobicistat


Cobicistat, sold under the brand name Tybost, is a medication for use in the treatment of human immunodeficiency virus infection (HIV/AIDS). Its major mechanism of action is through the inhibition of human CYP3A proteins.

Like ritonavir (Norvir), cobicistat is of interest for its ability to inhibit liver enzymes that metabolize other medications used to treat HIV, notably elvitegravir, an HIV integrase inhibitor. By combining cobicistat with elvitegravir, higher concentrations of the latter are achieved in the body with lower dosing, theoretically enhancing elvitegravir's viral suppression while diminishing its adverse side-effects. In contrast with ritonavir, the only other booster approved for use as a part of HAART, cobicistat has no anti-HIV activity of its own.

Cobicistat is a component of three four-drug, fixed-dose combination HIV treatments. The first, elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil, is marketed as Stribild and was approved by the FDA in August 2012 for use in the United States. The second, elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide, is marketed as Genvoya and was approved by the FDA in November 2015 for use in the United States. Both Stribild and Genvoya are owned by Gilead Sciences. The third, cobicistat, darunavir, emtricitabine, and tenofovir alafenamide, is marketed as Symtuza and was FDA approved July 17, 2018 and is owned by Janssen Pharmaceuticals.

Additionally, in existence are a fixed-dose combination of cobicistat and protease inhibitor darunavir (darunavir/cobicistat; marketed as Prezcobix by Janssen Therapeutics), and a fixed-dose combination of cobicistat and protease inhibitor atazanavir (atazanavir/cobicistat; marketed as Evotaz by Bristol-Myers Squibb). Both Prezcobix and Evotaz were approved by the FDA in January 2015.

Cobicistat is a potent inhibitor of cytochrome P450 3A enzymes, including the important CYP3A4 subtype. It also inhibits intestinal transport proteins, increasing the overall absorption of several HIV medications, including atazanavir, darunavir, and tenofovir alafenamide.

Related products

Looking for a discounted price or need more info for 'N-Methyl-2-(1-methylethyl)-4-thiazolemethanamine dihydrochloride (CS-O-10629)' ?

If you are looking for Bulk purchase, Discounted Price, etc. please share your email and the exact quantity you are looking for, our team will respond to you within 30 mins with all the required information.

Looking for a discounted price or need more info for 'N-Methyl-2-(1-methylethyl)-4-thiazolemethanamine dihydrochloride (CS-O-10629)' ?

If you are looking for Bulk purchase, Discounted Price, etc. please share your email and the exact quantity you are looking for, our team will respond to you within 30 mins with all the required information.